Background: While preclinical studies suggest that Phosphodiesterase 5 (PDE5) inhibition may reduce cognitive impairment, findings from observational studies on whether PDE5 inhibitors reduce Alzheimer’s disease (AD) risk have been inconsistent.
Objective: To perform a two-sample cis-Mendelian randomisation analysis to estimate the effect of PDE5 inhibition on AD risk.
For more information, see the pre-print here.